News & Updates
Filter by Specialty:
40 COVID-19 vaccines and counting: Do we still need more?
There are currently 40 approved vaccines against COVID-19, of which 11 have been granted Emergency Use Authorization by the World Health Organization. [covid19.trackvaccines.org/vaccines/approved] With over 300 other candidates in the development pipeline – over 100 of which are in clinical testing [vac-lshtm.shinyapps.io/ncov_vaccine_landscape] – are new vaccines necessary?
40 COVID-19 vaccines and counting: Do we still need more?
22 Jul 2022Ribociclib–binimetinib combo safe, effective in NRAS-mutant melanoma
Treatment with the combination of ribociclib plus binimetinib appears to be well tolerated and delivers modest clinical activity in patients with locally advanced or metastatic melanoma harbouring NRAS mutation, according to the results of a phase Ib/II study.
Ribociclib–binimetinib combo safe, effective in NRAS-mutant melanoma
22 Jul 2022Saliva biomarkers can help predict diabetic neuropathy in type 1 diabetes
Salivary levels of the inflammatory biomarker immunoglobulin A (IgA) appear to be significantly suppressed in type 1 diabetes mellitus (DM) patients with neuropathy (DMN), reports a recent study.
Saliva biomarkers can help predict diabetic neuropathy in type 1 diabetes
21 Jul 2022Investigational nitric oxide gel for water warts scores high in phase III trial
A novel nitric oxide-releasing gel, berdazimer 10.3%, proves effective in the treatment of patients with water warts or molluscum contagiosum skin infection, facilitating clearance of lesions with low adverse event rates, as shown in the phase III B-SIMPLE4 trial.
Investigational nitric oxide gel for water warts scores high in phase III trial
21 Jul 2022Lifestyle changes improve cognition among people with resistant hypertension
Individuals with resistant hypertension who undergo lifestyle modification have better cognitive function, and this benefit may be attributed to the reduced ambulatory systolic blood pressure (SBP) changes through weight loss, suggests a study.
Lifestyle changes improve cognition among people with resistant hypertension
21 Jul 20226-month secukinumab use improves outcomes in psoriatic arthritis
Real-world patients with psoriatic arthritis (PsA) who received and remained on secukinumab treatment for 6 months has attained minimal disease activity (MDA) and shown improvements in clinical manifestations, patient-reported outcomes, and work productivity at follow-up, reveals a study. The results are consistent with findings from clinical trials.